| 產(chǎn)品名稱 | ZCL 278 |
| 產(chǎn)品貨號 | Axon 2138 CAS [587841-73-4] MF C21H19BrClN5O4S2MW 584.89 Purity: 98% Soluble in DMSO Description Selective Cdc42 GTPase inhibitor. ZCL 278 specifically targets Cdc42–ITSN interaction and inhibits Cdc42-mediated cellular processes, thus providing a powerful tool for research of Cdc42 subclass of Rho GTPases in human pathogenesis. ZCL 278 reduces the perinuclear accumulation of active Cdc42 in contrast to NSC 23766 (Axon 1578), a selective Rac inhibitor. References Certificates Categories Extra info A Friesland et al. Small molecule targeting Cdc42–intersectin interaction disrupts Golgi origanization and suppresses cell motility. Proc. Natl Acad. Sci. USA. 2013, 110, 1261-1266.? Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Cell Signaling & Oncology Stem Cell Cdc42 p53-Tumor Suppression EC 3.6.5.2 Cdc42 GTPase inhibitor, targeting Cdc42–ITSN interaction Chemical name 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenylcarbamothioyl)acetamide Parent CAS No. [587841-73-4] Order Size Unit Price Stock 10 mg €105.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
ZCL 278Axon 2138 CAS [587841-73-4] MF C21H19BrClN5O4S2
DescriptionSelective Cdc42 GTPase inhibitor. ZCL 278 specifically targets Cdc42–ITSN interaction and inhibits Cdc42-mediated cellular processes, thus providing a powerful tool for research of Cdc42 subclass of Rho GTPases in human pathogenesis. ZCL 278 reduces the perinuclear accumulation of active Cdc42 in contrast to NSC 23766 (Axon 1578), a selective Rac inhibitor.
Cdc42 GTPase inhibitor, targeting Cdc42–ITSN interaction
Chemical name2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenylcarbamothioyl)acetamide Parent CAS No.[587841-73-4] |
| 產(chǎn)品資料 |
